MeiraGTx Holdings plc reported second quarter 2026 financial results and provided a corporate update. The company acquired full rights to botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for a $25 million upfront payment, with potential regulatory and commercial milestones. MeiraGTx secured up to $400 million in strategic investment from Oberland Capital, including an initial $135 million comprising $125 million in cash and $10 million in equity. The company reported net income of $160.7 million, or $1.76 basic earnings per share, compared to a net loss of $38.8 million in the prior year period. Revenue increased significantly to $321.4 million, driven by license and service revenue from collaborations with Eli Lilly and Reogen. MeiraGTx also announced the appointment of Penny Fleck as Chief Development Officer and John Knighton as Executive Vice President of Global Manufacturing and Supply Chain. The company operates in the biotechnology industry, developing clinical-stage genetic medicines for inherited and acquired diseases.

MeiraGTx Holdings plc entered into a Royalty Note Purchase Agreement for up to $375 million in senior secured royalty notes, with an initial $100 million purchase on June 30, 2026, and a second $25 million purchase scheduled for July 17, 2026. The agreement includes options for additional purchases based on clinical data or regulatory approvals. Additionally, the company entered into a securities purchase agreement with TPC Investments for $10.0 million via the issuance of 950,570 ordinary shares at $10.52 per share. MeiraGTx is a biotechnology company focused on gene therapy development.